nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—BLK—systemic scleroderma	0.351	1	CbGaD
Sunitinib—PTK2B—Leflunomide—systemic scleroderma	0.197	0.678	CbGbCtD
Sunitinib—ABCG2—Leflunomide—systemic scleroderma	0.0187	0.0643	CbGbCtD
Sunitinib—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0128	0.0439	CbGbCtD
Sunitinib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0116	0.0397	CbGbCtD
Sunitinib—ABCC4—Methotrexate—systemic scleroderma	0.00862	0.0296	CbGbCtD
Sunitinib—ABCB1—Lisinopril—systemic scleroderma	0.00707	0.0243	CbGbCtD
Sunitinib—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.00641	0.022	CbGbCtD
Sunitinib—ABCB1—Captopril—systemic scleroderma	0.0053	0.0182	CbGbCtD
Sunitinib—ABCC2—Methotrexate—systemic scleroderma	0.00513	0.0176	CbGbCtD
Sunitinib—ABCG2—Methotrexate—systemic scleroderma	0.00464	0.0159	CbGbCtD
Sunitinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00417	0.0143	CbGbCtD
Sunitinib—ABCB1—Prednisone—systemic scleroderma	0.00333	0.0114	CbGbCtD
Sunitinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0025	0.00858	CbGbCtD
Sunitinib—CYP3A4—Prednisone—systemic scleroderma	0.002	0.00686	CbGbCtD
Sunitinib—ABCB1—Methotrexate—systemic scleroderma	0.00167	0.00574	CbGbCtD
Sunitinib—DYRK1A—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00115	0.45	CbGdCrCtD
Sunitinib—PRPF4—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.000989	0.388	CbGdCrCtD
Sunitinib—CLK1—connective tissue—systemic scleroderma	0.000298	0.00301	CbGeAlD
Sunitinib—DAPK1—lung—systemic scleroderma	0.000296	0.003	CbGeAlD
Sunitinib—PRPF4B—digestive system—systemic scleroderma	0.000295	0.00299	CbGeAlD
Sunitinib—RPS6KA2—tendon—systemic scleroderma	0.000294	0.00297	CbGeAlD
Sunitinib—STK38—tendon—systemic scleroderma	0.000294	0.00297	CbGeAlD
Sunitinib—BMP2K—connective tissue—systemic scleroderma	0.000292	0.00296	CbGeAlD
Sunitinib—AURKC—tendon—systemic scleroderma	0.000292	0.00295	CbGeAlD
Sunitinib—PKN1—tendon—systemic scleroderma	0.000289	0.00293	CbGeAlD
Sunitinib—CSNK1G2—tendon—systemic scleroderma	0.000289	0.00293	CbGeAlD
Sunitinib—MAP4K4—smooth muscle tissue—systemic scleroderma	0.000288	0.00291	CbGeAlD
Sunitinib—CSNK2A1—digestive system—systemic scleroderma	0.000287	0.00291	CbGeAlD
Sunitinib—STK11—lung—systemic scleroderma	0.000287	0.0029	CbGeAlD
Sunitinib—BRD4—lung—systemic scleroderma	0.000287	0.0029	CbGeAlD
Sunitinib—PRKAA1—connective tissue—systemic scleroderma	0.000285	0.00289	CbGeAlD
Sunitinib—PRPF4—tendon—systemic scleroderma	0.000285	0.00288	CbGeAlD
Sunitinib—RIOK1—lung—systemic scleroderma	0.000284	0.00287	CbGeAlD
Sunitinib—RPS6KA1—lung—systemic scleroderma	0.000284	0.00287	CbGeAlD
Sunitinib—MYLK—digestive system—systemic scleroderma	0.000284	0.00287	CbGeAlD
Sunitinib—PTK2B—connective tissue—systemic scleroderma	0.000282	0.00285	CbGeAlD
Sunitinib—PRPF4B—tendon—systemic scleroderma	0.000281	0.00284	CbGeAlD
Sunitinib—MARK2—lung—systemic scleroderma	0.000279	0.00282	CbGeAlD
Sunitinib—TNIK—lung—systemic scleroderma	0.000279	0.00282	CbGeAlD
Sunitinib—STK4—digestive system—systemic scleroderma	0.000279	0.00282	CbGeAlD
Sunitinib—MAP2K1—smooth muscle tissue—systemic scleroderma	0.000278	0.00281	CbGeAlD
Sunitinib—STK39—tendon—systemic scleroderma	0.000277	0.0028	CbGeAlD
Sunitinib—SGK3—lung—systemic scleroderma	0.000276	0.00279	CbGeAlD
Sunitinib—MAP2K1—skin of body—systemic scleroderma	0.000274	0.00277	CbGeAlD
Sunitinib—CSNK1A1—smooth muscle tissue—systemic scleroderma	0.000274	0.00277	CbGeAlD
Sunitinib—ICK—lung—systemic scleroderma	0.000274	0.00277	CbGeAlD
Sunitinib—CSNK2A1—tendon—systemic scleroderma	0.000274	0.00277	CbGeAlD
Sunitinib—CSNK1A1—skin of body—systemic scleroderma	0.000271	0.00274	CbGeAlD
Sunitinib—MAP3K2—connective tissue—systemic scleroderma	0.000265	0.00268	CbGeAlD
Sunitinib—STK16—digestive system—systemic scleroderma	0.000265	0.00268	CbGeAlD
Sunitinib—NUAK1—lung—systemic scleroderma	0.000264	0.00267	CbGeAlD
Sunitinib—CHEK2—lung—systemic scleroderma	0.000264	0.00267	CbGeAlD
Sunitinib—HIPK3—digestive system—systemic scleroderma	0.000263	0.00266	CbGeAlD
Sunitinib—ALK—digestive system—systemic scleroderma	0.000263	0.00266	CbGeAlD
Sunitinib—HIPK2—digestive system—systemic scleroderma	0.000263	0.00266	CbGeAlD
Sunitinib—INSR—lung—systemic scleroderma	0.000262	0.00265	CbGeAlD
Sunitinib—OXSR1—lung—systemic scleroderma	0.000262	0.00265	CbGeAlD
Sunitinib—SNRK—lung—systemic scleroderma	0.000262	0.00265	CbGeAlD
Sunitinib—PHKG2—tendon—systemic scleroderma	0.00026	0.00263	CbGeAlD
Sunitinib—STK24—tendon—systemic scleroderma	0.000259	0.00262	CbGeAlD
Sunitinib—PTK2B—smooth muscle tissue—systemic scleroderma	0.000258	0.00261	CbGeAlD
Sunitinib—TYK2—connective tissue—systemic scleroderma	0.000258	0.00261	CbGeAlD
Sunitinib—RPS6KA2—lung—systemic scleroderma	0.000258	0.00261	CbGeAlD
Sunitinib—STK38—lung—systemic scleroderma	0.000258	0.00261	CbGeAlD
Sunitinib—DAPK2—tendon—systemic scleroderma	0.000256	0.00259	CbGeAlD
Sunitinib—CSNK1G2—lung—systemic scleroderma	0.000254	0.00257	CbGeAlD
Sunitinib—PKN1—lung—systemic scleroderma	0.000254	0.00257	CbGeAlD
Sunitinib—STK16—tendon—systemic scleroderma	0.000252	0.00255	CbGeAlD
Sunitinib—CSNK1E—skin of body—systemic scleroderma	0.000251	0.00254	CbGeAlD
Sunitinib—HIPK3—tendon—systemic scleroderma	0.000251	0.00253	CbGeAlD
Sunitinib—HIPK2—tendon—systemic scleroderma	0.000251	0.00253	CbGeAlD
Sunitinib—PRPF4—lung—systemic scleroderma	0.00025	0.00253	CbGeAlD
Sunitinib—RPS6KB1—connective tissue—systemic scleroderma	0.00025	0.00253	CbGeAlD
Sunitinib—RET—connective tissue—systemic scleroderma	0.000248	0.00251	CbGeAlD
Sunitinib—RIOK2—tendon—systemic scleroderma	0.000248	0.00251	CbGeAlD
Sunitinib—TNK1—tendon—systemic scleroderma	0.000248	0.00251	CbGeAlD
Sunitinib—AXL—connective tissue—systemic scleroderma	0.000247	0.0025	CbGeAlD
Sunitinib—PRPF4B—lung—systemic scleroderma	0.000247	0.00249	CbGeAlD
Sunitinib—MAP4K1—tendon—systemic scleroderma	0.000245	0.00248	CbGeAlD
Sunitinib—MAP2K2—smooth muscle tissue—systemic scleroderma	0.000245	0.00247	CbGeAlD
Sunitinib—STK39—lung—systemic scleroderma	0.000243	0.00246	CbGeAlD
Sunitinib—ROCK1—digestive system—systemic scleroderma	0.000243	0.00246	CbGeAlD
Sunitinib—MAP2K2—skin of body—systemic scleroderma	0.000241	0.00244	CbGeAlD
Sunitinib—DAPK3—tendon—systemic scleroderma	0.000241	0.00243	CbGeAlD
Sunitinib—MAP3K7—smooth muscle tissue—systemic scleroderma	0.00024	0.00243	CbGeAlD
Sunitinib—CSNK2A1—lung—systemic scleroderma	0.00024	0.00243	CbGeAlD
Sunitinib—CLK2—tendon—systemic scleroderma	0.000238	0.00241	CbGeAlD
Sunitinib—MAP4K2—tendon—systemic scleroderma	0.000237	0.0024	CbGeAlD
Sunitinib—MYLK—lung—systemic scleroderma	0.000237	0.0024	CbGeAlD
Sunitinib—TYK2—smooth muscle tissue—systemic scleroderma	0.000236	0.00239	CbGeAlD
Sunitinib—FGFR2—connective tissue—systemic scleroderma	0.000236	0.00239	CbGeAlD
Sunitinib—JAK2—connective tissue—systemic scleroderma	0.000235	0.00238	CbGeAlD
Sunitinib—STK3—tendon—systemic scleroderma	0.000234	0.00237	CbGeAlD
Sunitinib—PLK4—lung—systemic scleroderma	0.000234	0.00237	CbGeAlD
Sunitinib—TYK2—skin of body—systemic scleroderma	0.000233	0.00236	CbGeAlD
Sunitinib—IRAK1—smooth muscle tissue—systemic scleroderma	0.000233	0.00236	CbGeAlD
Sunitinib—STK4—lung—systemic scleroderma	0.000233	0.00235	CbGeAlD
Sunitinib—FYN—connective tissue—systemic scleroderma	0.000232	0.00234	CbGeAlD
Sunitinib—RPS6KB1—smooth muscle tissue—systemic scleroderma	0.000229	0.00231	CbGeAlD
Sunitinib—PHKG2—lung—systemic scleroderma	0.000229	0.00231	CbGeAlD
Sunitinib—STK24—lung—systemic scleroderma	0.000227	0.0023	CbGeAlD
Sunitinib—MAP4K4—digestive system—systemic scleroderma	0.000227	0.0023	CbGeAlD
Sunitinib—AXL—smooth muscle tissue—systemic scleroderma	0.000226	0.00229	CbGeAlD
Sunitinib—DAPK2—lung—systemic scleroderma	0.000225	0.00227	CbGeAlD
Sunitinib—AXL—skin of body—systemic scleroderma	0.000223	0.00226	CbGeAlD
Sunitinib—STK16—lung—systemic scleroderma	0.000221	0.00224	CbGeAlD
Sunitinib—MERTK—tendon—systemic scleroderma	0.00022	0.00223	CbGeAlD
Sunitinib—HIPK2—lung—systemic scleroderma	0.00022	0.00222	CbGeAlD
Sunitinib—HIPK3—lung—systemic scleroderma	0.00022	0.00222	CbGeAlD
Sunitinib—ALK—lung—systemic scleroderma	0.00022	0.00222	CbGeAlD
Sunitinib—MAP2K1—digestive system—systemic scleroderma	0.000219	0.00222	CbGeAlD
Sunitinib—FLT1—connective tissue—systemic scleroderma	0.000219	0.00221	CbGeAlD
Sunitinib—RIOK2—lung—systemic scleroderma	0.000218	0.0022	CbGeAlD
Sunitinib—TNK1—lung—systemic scleroderma	0.000218	0.0022	CbGeAlD
Sunitinib—CSNK1A1—digestive system—systemic scleroderma	0.000216	0.00219	CbGeAlD
Sunitinib—MAP4K4—tendon—systemic scleroderma	0.000216	0.00219	CbGeAlD
Sunitinib—FGFR2—smooth muscle tissue—systemic scleroderma	0.000216	0.00218	CbGeAlD
Sunitinib—MAP4K1—lung—systemic scleroderma	0.000215	0.00218	CbGeAlD
Sunitinib—MAP3K19—lung—systemic scleroderma	0.000215	0.00218	CbGeAlD
Sunitinib—CLK1—digestive system—systemic scleroderma	0.000215	0.00218	CbGeAlD
Sunitinib—JAK2—smooth muscle tissue—systemic scleroderma	0.000215	0.00217	CbGeAlD
Sunitinib—FGFR2—skin of body—systemic scleroderma	0.000213	0.00216	CbGeAlD
Sunitinib—MAP3K12—tendon—systemic scleroderma	0.000213	0.00215	CbGeAlD
Sunitinib—JAK2—skin of body—systemic scleroderma	0.000212	0.00215	CbGeAlD
Sunitinib—FYN—smooth muscle tissue—systemic scleroderma	0.000212	0.00214	CbGeAlD
Sunitinib—DAPK3—lung—systemic scleroderma	0.000211	0.00214	CbGeAlD
Sunitinib—CAMK2G—digestive system—systemic scleroderma	0.000211	0.00214	CbGeAlD
Sunitinib—RPS6KA3—tendon—systemic scleroderma	0.00021	0.00213	CbGeAlD
Sunitinib—CLK2—lung—systemic scleroderma	0.000209	0.00212	CbGeAlD
Sunitinib—FYN—skin of body—systemic scleroderma	0.000209	0.00212	CbGeAlD
Sunitinib—YES1—connective tissue—systemic scleroderma	0.000209	0.00211	CbGeAlD
Sunitinib—MAP4K2—lung—systemic scleroderma	0.000208	0.00211	CbGeAlD
Sunitinib—MAP4K5—smooth muscle tissue—systemic scleroderma	0.000207	0.00209	CbGeAlD
Sunitinib—TAOK3—connective tissue—systemic scleroderma	0.000206	0.00209	CbGeAlD
Sunitinib—PRKAA1—digestive system—systemic scleroderma	0.000206	0.00209	CbGeAlD
Sunitinib—CSNK1A1—tendon—systemic scleroderma	0.000206	0.00208	CbGeAlD
Sunitinib—STK3—lung—systemic scleroderma	0.000205	0.00208	CbGeAlD
Sunitinib—PDGFRA—connective tissue—systemic scleroderma	0.000205	0.00207	CbGeAlD
Sunitinib—CLK1—tendon—systemic scleroderma	0.000205	0.00207	CbGeAlD
Sunitinib—MAP3K3—skin of body—systemic scleroderma	0.000204	0.00207	CbGeAlD
Sunitinib—PTK2B—digestive system—systemic scleroderma	0.000204	0.00206	CbGeAlD
Sunitinib—ROCK1—lung—systemic scleroderma	0.000203	0.00205	CbGeAlD
Sunitinib—CAMK2G—tendon—systemic scleroderma	0.000201	0.00203	CbGeAlD
Sunitinib—BMP2K—tendon—systemic scleroderma	0.000201	0.00203	CbGeAlD
Sunitinib—CSNK1E—digestive system—systemic scleroderma	0.000201	0.00203	CbGeAlD
Sunitinib—FLT1—smooth muscle tissue—systemic scleroderma	0.0002	0.00202	CbGeAlD
Sunitinib—LRRK2—tendon—systemic scleroderma	0.000199	0.00201	CbGeAlD
Sunitinib—DYRK1A—lung—systemic scleroderma	0.000198	0.002	CbGeAlD
Sunitinib—EPHB6—skin of body—systemic scleroderma	0.000195	0.00198	CbGeAlD
Sunitinib—PTK2B—tendon—systemic scleroderma	0.000194	0.00196	CbGeAlD
Sunitinib—MERTK—lung—systemic scleroderma	0.000193	0.00195	CbGeAlD
Sunitinib—MAP2K2—digestive system—systemic scleroderma	0.000193	0.00195	CbGeAlD
Sunitinib—ULK3—digestive system—systemic scleroderma	0.000193	0.00195	CbGeAlD
Sunitinib—YES1—smooth muscle tissue—systemic scleroderma	0.000191	0.00193	CbGeAlD
Sunitinib—CSNK1E—tendon—systemic scleroderma	0.000191	0.00193	CbGeAlD
Sunitinib—FGFR1—tendon—systemic scleroderma	0.000191	0.00193	CbGeAlD
Sunitinib—MAP4K4—lung—systemic scleroderma	0.00019	0.00192	CbGeAlD
Sunitinib—NUAK2—lung—systemic scleroderma	0.000188	0.0019	CbGeAlD
Sunitinib—IRAK4—tendon—systemic scleroderma	0.000188	0.0019	CbGeAlD
Sunitinib—TBK1—digestive system—systemic scleroderma	0.000188	0.0019	CbGeAlD
Sunitinib—PDGFRA—smooth muscle tissue—systemic scleroderma	0.000188	0.0019	CbGeAlD
Sunitinib—FLT3—lung—systemic scleroderma	0.000187	0.00189	CbGeAlD
Sunitinib—MAP3K12—lung—systemic scleroderma	0.000187	0.00189	CbGeAlD
Sunitinib—TYK2—digestive system—systemic scleroderma	0.000186	0.00189	CbGeAlD
Sunitinib—KDR—connective tissue—systemic scleroderma	0.000185	0.00187	CbGeAlD
Sunitinib—RPS6KA3—lung—systemic scleroderma	0.000184	0.00186	CbGeAlD
Sunitinib—ULK3—tendon—systemic scleroderma	0.000184	0.00186	CbGeAlD
Sunitinib—MAP2K2—tendon—systemic scleroderma	0.000184	0.00186	CbGeAlD
Sunitinib—MAP2K1—lung—systemic scleroderma	0.000183	0.00185	CbGeAlD
Sunitinib—CSNK1A1—lung—systemic scleroderma	0.000181	0.00183	CbGeAlD
Sunitinib—MAP3K7—tendon—systemic scleroderma	0.000181	0.00183	CbGeAlD
Sunitinib—RPS6KB1—digestive system—systemic scleroderma	0.000181	0.00183	CbGeAlD
Sunitinib—CSF1R—connective tissue—systemic scleroderma	0.000181	0.00183	CbGeAlD
Sunitinib—CLK1—lung—systemic scleroderma	0.00018	0.00182	CbGeAlD
Sunitinib—RET—digestive system—systemic scleroderma	0.000179	0.00182	CbGeAlD
Sunitinib—FGR—digestive system—systemic scleroderma	0.000179	0.00182	CbGeAlD
Sunitinib—TBK1—tendon—systemic scleroderma	0.000179	0.00181	CbGeAlD
Sunitinib—TYK2—tendon—systemic scleroderma	0.000177	0.00179	CbGeAlD
Sunitinib—CAMK2G—lung—systemic scleroderma	0.000176	0.00178	CbGeAlD
Sunitinib—BMP2K—lung—systemic scleroderma	0.000176	0.00178	CbGeAlD
Sunitinib—IRAK1—tendon—systemic scleroderma	0.000175	0.00177	CbGeAlD
Sunitinib—LRRK2—lung—systemic scleroderma	0.000175	0.00177	CbGeAlD
Sunitinib—PRKAA1—lung—systemic scleroderma	0.000172	0.00174	CbGeAlD
Sunitinib—RPS6KB1—tendon—systemic scleroderma	0.000172	0.00174	CbGeAlD
Sunitinib—FGR—tendon—systemic scleroderma	0.000171	0.00173	CbGeAlD
Sunitinib—RET—tendon—systemic scleroderma	0.000171	0.00173	CbGeAlD
Sunitinib—FGFR2—digestive system—systemic scleroderma	0.000171	0.00172	CbGeAlD
Sunitinib—PTK2B—lung—systemic scleroderma	0.00017	0.00172	CbGeAlD
Sunitinib—AXL—tendon—systemic scleroderma	0.00017	0.00172	CbGeAlD
Sunitinib—FLT4—lung—systemic scleroderma	0.00017	0.00172	CbGeAlD
Sunitinib—JAK2—digestive system—systemic scleroderma	0.00017	0.00172	CbGeAlD
Sunitinib—KDR—smooth muscle tissue—systemic scleroderma	0.000169	0.00171	CbGeAlD
Sunitinib—CSNK1E—lung—systemic scleroderma	0.000167	0.00169	CbGeAlD
Sunitinib—FGFR1—lung—systemic scleroderma	0.000167	0.00169	CbGeAlD
Sunitinib—FYN—digestive system—systemic scleroderma	0.000167	0.00169	CbGeAlD
Sunitinib—CSF1R—smooth muscle tissue—systemic scleroderma	0.000165	0.00167	CbGeAlD
Sunitinib—IRAK4—lung—systemic scleroderma	0.000165	0.00167	CbGeAlD
Sunitinib—KIT—connective tissue—systemic scleroderma	0.000164	0.00166	CbGeAlD
Sunitinib—SLK—tendon—systemic scleroderma	0.000164	0.00166	CbGeAlD
Sunitinib—CSF1R—skin of body—systemic scleroderma	0.000163	0.00165	CbGeAlD
Sunitinib—JAK2—tendon—systemic scleroderma	0.000161	0.00163	CbGeAlD
Sunitinib—MAP2K2—lung—systemic scleroderma	0.000161	0.00163	CbGeAlD
Sunitinib—ULK3—lung—systemic scleroderma	0.000161	0.00163	CbGeAlD
Sunitinib—PDGFRB—connective tissue—systemic scleroderma	0.00016	0.00162	CbGeAlD
Sunitinib—MAP3K2—lung—systemic scleroderma	0.00016	0.00162	CbGeAlD
Sunitinib—FYN—tendon—systemic scleroderma	0.000159	0.00161	CbGeAlD
Sunitinib—MAP3K7—lung—systemic scleroderma	0.000159	0.0016	CbGeAlD
Sunitinib—FLT1—digestive system—systemic scleroderma	0.000158	0.0016	CbGeAlD
Sunitinib—TBK1—lung—systemic scleroderma	0.000157	0.00159	CbGeAlD
Sunitinib—TYK2—lung—systemic scleroderma	0.000156	0.00158	CbGeAlD
Sunitinib—MAP3K3—tendon—systemic scleroderma	0.000156	0.00157	CbGeAlD
Sunitinib—MAP4K5—tendon—systemic scleroderma	0.000156	0.00157	CbGeAlD
Sunitinib—IRAK1—lung—systemic scleroderma	0.000154	0.00155	CbGeAlD
Sunitinib—YES1—digestive system—systemic scleroderma	0.000151	0.00153	CbGeAlD
Sunitinib—RPS6KB1—lung—systemic scleroderma	0.000151	0.00153	CbGeAlD
Sunitinib—FLT1—tendon—systemic scleroderma	0.00015	0.00152	CbGeAlD
Sunitinib—KIT—smooth muscle tissue—systemic scleroderma	0.00015	0.00152	CbGeAlD
Sunitinib—FGR—lung—systemic scleroderma	0.00015	0.00152	CbGeAlD
Sunitinib—STK10—digestive system—systemic scleroderma	0.00015	0.00151	CbGeAlD
Sunitinib—AXL—lung—systemic scleroderma	0.000149	0.00151	CbGeAlD
Sunitinib—TAOK3—digestive system—systemic scleroderma	0.000149	0.00151	CbGeAlD
Sunitinib—EPHB6—tendon—systemic scleroderma	0.000149	0.0015	CbGeAlD
Sunitinib—PDGFRA—digestive system—systemic scleroderma	0.000148	0.0015	CbGeAlD
Sunitinib—KIT—skin of body—systemic scleroderma	0.000148	0.0015	CbGeAlD
Sunitinib—PDGFRB—smooth muscle tissue—systemic scleroderma	0.000146	0.00148	CbGeAlD
Sunitinib—PDGFRB—skin of body—systemic scleroderma	0.000145	0.00146	CbGeAlD
Sunitinib—SLK—lung—systemic scleroderma	0.000144	0.00145	CbGeAlD
Sunitinib—YES1—tendon—systemic scleroderma	0.000144	0.00145	CbGeAlD
Sunitinib—FGFR2—lung—systemic scleroderma	0.000142	0.00144	CbGeAlD
Sunitinib—STK10—tendon—systemic scleroderma	0.000142	0.00144	CbGeAlD
Sunitinib—TAOK3—tendon—systemic scleroderma	0.000142	0.00143	CbGeAlD
Sunitinib—JAK2—lung—systemic scleroderma	0.000142	0.00143	CbGeAlD
Sunitinib—PDGFRA—tendon—systemic scleroderma	0.000141	0.00143	CbGeAlD
Sunitinib—FYN—lung—systemic scleroderma	0.00014	0.00141	CbGeAlD
Sunitinib—MAP3K3—lung—systemic scleroderma	0.000137	0.00138	CbGeAlD
Sunitinib—MAP4K5—lung—systemic scleroderma	0.000137	0.00138	CbGeAlD
Sunitinib—KDR—digestive system—systemic scleroderma	0.000134	0.00135	CbGeAlD
Sunitinib—FLT1—lung—systemic scleroderma	0.000132	0.00134	CbGeAlD
Sunitinib—EPHB6—lung—systemic scleroderma	0.00013	0.00132	CbGeAlD
Sunitinib—CSF1R—digestive system—systemic scleroderma	0.00013	0.00132	CbGeAlD
Sunitinib—MAP2K5—tendon—systemic scleroderma	0.000127	0.00129	CbGeAlD
Sunitinib—KDR—tendon—systemic scleroderma	0.000127	0.00129	CbGeAlD
Sunitinib—YES1—lung—systemic scleroderma	0.000126	0.00128	CbGeAlD
Sunitinib—STK10—lung—systemic scleroderma	0.000125	0.00126	CbGeAlD
Sunitinib—TAOK3—lung—systemic scleroderma	0.000124	0.00126	CbGeAlD
Sunitinib—CSF1R—tendon—systemic scleroderma	0.000124	0.00126	CbGeAlD
Sunitinib—PDGFRA—lung—systemic scleroderma	0.000124	0.00125	CbGeAlD
Sunitinib—KIT—digestive system—systemic scleroderma	0.000118	0.0012	CbGeAlD
Sunitinib—PDGFRB—digestive system—systemic scleroderma	0.000116	0.00117	CbGeAlD
Sunitinib—KDR—lung—systemic scleroderma	0.000112	0.00113	CbGeAlD
Sunitinib—MAP2K5—lung—systemic scleroderma	0.000112	0.00113	CbGeAlD
Sunitinib—PDGFRB—tendon—systemic scleroderma	0.00011	0.00111	CbGeAlD
Sunitinib—CSF1R—lung—systemic scleroderma	0.000109	0.0011	CbGeAlD
Sunitinib—KIT—lung—systemic scleroderma	9.89e-05	0.001	CbGeAlD
Sunitinib—PDGFRB—lung—systemic scleroderma	9.66e-05	0.000977	CbGeAlD
Sunitinib—CSNK1E—Dexamethasone—Mometasone—systemic scleroderma	9.38e-05	0.0369	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Mometasone—systemic scleroderma	9.38e-05	0.0369	CbGdCrCtD
Sunitinib—ABCC4—digestive system—systemic scleroderma	9.21e-05	0.000931	CbGeAlD
Sunitinib—ABCC2—digestive system—systemic scleroderma	8.91e-05	0.000902	CbGeAlD
Sunitinib—ABCC4—tendon—systemic scleroderma	8.76e-05	0.000886	CbGeAlD
Sunitinib—ABCB1—blood vessel—systemic scleroderma	8.66e-05	0.000876	CbGeAlD
Sunitinib—ABCC2—tendon—systemic scleroderma	8.48e-05	0.000858	CbGeAlD
Sunitinib—CSNK1E—Danazol—Prednisone—systemic scleroderma	8.01e-05	0.0315	CbGdCrCtD
Sunitinib—ABCC4—lung—systemic scleroderma	7.69e-05	0.000778	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	6.97e-05	0.000525	CcSEcCtD
Sunitinib—Gastrointestinal pain—Azathioprine—systemic scleroderma	6.94e-05	0.000524	CcSEcCtD
Sunitinib—Headache—Mometasone—systemic scleroderma	6.94e-05	0.000523	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	6.92e-05	0.000522	CcSEcCtD
Sunitinib—Insomnia—Mycophenolic acid—systemic scleroderma	6.92e-05	0.000522	CcSEcCtD
Sunitinib—Fatigue—Leflunomide—systemic scleroderma	6.91e-05	0.000521	CcSEcCtD
Sunitinib—Oedema—Lisinopril—systemic scleroderma	6.89e-05	0.000519	CcSEcCtD
Sunitinib—Pruritus—Captopril—systemic scleroderma	6.88e-05	0.000519	CcSEcCtD
Sunitinib—Paraesthesia—Mycophenolic acid—systemic scleroderma	6.87e-05	0.000518	CcSEcCtD
Sunitinib—Pain—Leflunomide—systemic scleroderma	6.85e-05	0.000517	CcSEcCtD
Sunitinib—Constipation—Leflunomide—systemic scleroderma	6.85e-05	0.000517	CcSEcCtD
Sunitinib—Infection—Lisinopril—systemic scleroderma	6.84e-05	0.000516	CcSEcCtD
Sunitinib—Anaemia—Mycophenolate mofetil—systemic scleroderma	6.83e-05	0.000515	CcSEcCtD
Sunitinib—Dyspnoea—Mycophenolic acid—systemic scleroderma	6.82e-05	0.000514	CcSEcCtD
Sunitinib—Shock—Lisinopril—systemic scleroderma	6.78e-05	0.000511	CcSEcCtD
Sunitinib—Angioedema—Mycophenolate mofetil—systemic scleroderma	6.76e-05	0.00051	CcSEcCtD
Sunitinib—Thrombocytopenia—Lisinopril—systemic scleroderma	6.74e-05	0.000509	CcSEcCtD
Sunitinib—Dyspepsia—Mycophenolic acid—systemic scleroderma	6.73e-05	0.000508	CcSEcCtD
Sunitinib—Neutropenia—Prednisone—systemic scleroderma	6.73e-05	0.000507	CcSEcCtD
Sunitinib—Abdominal pain—Azathioprine—systemic scleroderma	6.71e-05	0.000506	CcSEcCtD
Sunitinib—Body temperature increased—Azathioprine—systemic scleroderma	6.71e-05	0.000506	CcSEcCtD
Sunitinib—Skin disorder—Lisinopril—systemic scleroderma	6.69e-05	0.000505	CcSEcCtD
Sunitinib—Diarrhoea—Captopril—systemic scleroderma	6.65e-05	0.000502	CcSEcCtD
Sunitinib—Decreased appetite—Mycophenolic acid—systemic scleroderma	6.65e-05	0.000501	CcSEcCtD
Sunitinib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	6.62e-05	0.000499	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	6.6e-05	0.000498	CcSEcCtD
Sunitinib—Fatigue—Mycophenolic acid—systemic scleroderma	6.59e-05	0.000497	CcSEcCtD
Sunitinib—Nausea—Mometasone—systemic scleroderma	6.58e-05	0.000496	CcSEcCtD
Sunitinib—Anorexia—Lisinopril—systemic scleroderma	6.57e-05	0.000495	CcSEcCtD
Sunitinib—Gastrointestinal pain—Leflunomide—systemic scleroderma	6.55e-05	0.000494	CcSEcCtD
Sunitinib—Pain—Mycophenolic acid—systemic scleroderma	6.54e-05	0.000493	CcSEcCtD
Sunitinib—Constipation—Mycophenolic acid—systemic scleroderma	6.54e-05	0.000493	CcSEcCtD
Sunitinib—Weight decreased—Prednisone—systemic scleroderma	6.51e-05	0.000491	CcSEcCtD
Sunitinib—Hyperglycaemia—Prednisone—systemic scleroderma	6.49e-05	0.000489	CcSEcCtD
Sunitinib—Cough—Mycophenolate mofetil—systemic scleroderma	6.45e-05	0.000487	CcSEcCtD
Sunitinib—Dizziness—Captopril—systemic scleroderma	6.43e-05	0.000485	CcSEcCtD
Sunitinib—Liver function test abnormal—Methotrexate—systemic scleroderma	6.42e-05	0.000484	CcSEcCtD
Sunitinib—Convulsion—Mycophenolate mofetil—systemic scleroderma	6.41e-05	0.000483	CcSEcCtD
Sunitinib—Depression—Prednisone—systemic scleroderma	6.4e-05	0.000482	CcSEcCtD
Sunitinib—Hypertension—Mycophenolate mofetil—systemic scleroderma	6.38e-05	0.000482	CcSEcCtD
Sunitinib—Abdominal pain—Leflunomide—systemic scleroderma	6.34e-05	0.000478	CcSEcCtD
Sunitinib—Body temperature increased—Leflunomide—systemic scleroderma	6.34e-05	0.000478	CcSEcCtD
Sunitinib—Acute coronary syndrome—Prednisone—systemic scleroderma	6.32e-05	0.000477	CcSEcCtD
Sunitinib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	6.3e-05	0.000475	CcSEcCtD
Sunitinib—Chest pain—Mycophenolate mofetil—systemic scleroderma	6.3e-05	0.000475	CcSEcCtD
Sunitinib—Myalgia—Mycophenolate mofetil—systemic scleroderma	6.3e-05	0.000475	CcSEcCtD
Sunitinib—Neuropathy peripheral—Prednisone—systemic scleroderma	6.29e-05	0.000474	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	6.28e-05	0.000473	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	6.26e-05	0.000472	CcSEcCtD
Sunitinib—Hypersensitivity—Azathioprine—systemic scleroderma	6.25e-05	0.000472	CcSEcCtD
Sunitinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	6.25e-05	0.000472	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	6.25e-05	0.000472	CcSEcCtD
Sunitinib—Insomnia—Lisinopril—systemic scleroderma	6.23e-05	0.00047	CcSEcCtD
Sunitinib—Paraesthesia—Lisinopril—systemic scleroderma	6.18e-05	0.000466	CcSEcCtD
Sunitinib—Vomiting—Captopril—systemic scleroderma	6.18e-05	0.000466	CcSEcCtD
Sunitinib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	6.16e-05	0.000464	CcSEcCtD
Sunitinib—Dyspnoea—Lisinopril—systemic scleroderma	6.14e-05	0.000463	CcSEcCtD
Sunitinib—Rash—Captopril—systemic scleroderma	6.13e-05	0.000463	CcSEcCtD
Sunitinib—Dermatitis—Captopril—systemic scleroderma	6.13e-05	0.000462	CcSEcCtD
Sunitinib—Headache—Captopril—systemic scleroderma	6.09e-05	0.00046	CcSEcCtD
Sunitinib—Dyspepsia—Lisinopril—systemic scleroderma	6.06e-05	0.000457	CcSEcCtD
Sunitinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	6.05e-05	0.000456	CcSEcCtD
Sunitinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	6.05e-05	0.000456	CcSEcCtD
Sunitinib—Oedema—Mycophenolate mofetil—systemic scleroderma	6.04e-05	0.000455	CcSEcCtD
Sunitinib—CYP3A5—digestive system—systemic scleroderma	6.03e-05	0.00061	CbGeAlD
Sunitinib—Infection—Mycophenolate mofetil—systemic scleroderma	6e-05	0.000452	CcSEcCtD
Sunitinib—Decreased appetite—Lisinopril—systemic scleroderma	5.99e-05	0.000452	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	5.95e-05	0.000448	CcSEcCtD
Sunitinib—Fatigue—Lisinopril—systemic scleroderma	5.94e-05	0.000448	CcSEcCtD
Sunitinib—Shock—Mycophenolate mofetil—systemic scleroderma	5.94e-05	0.000448	CcSEcCtD
Sunitinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	5.92e-05	0.000446	CcSEcCtD
Sunitinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	5.91e-05	0.000446	CcSEcCtD
Sunitinib—Hypersensitivity—Leflunomide—systemic scleroderma	5.91e-05	0.000445	CcSEcCtD
Sunitinib—Pancreatitis—Methotrexate—systemic scleroderma	5.89e-05	0.000445	CcSEcCtD
Sunitinib—Pain—Lisinopril—systemic scleroderma	5.89e-05	0.000444	CcSEcCtD
Sunitinib—Constipation—Lisinopril—systemic scleroderma	5.89e-05	0.000444	CcSEcCtD
Sunitinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	5.86e-05	0.000442	CcSEcCtD
Sunitinib—Bradycardia—Prednisone—systemic scleroderma	5.86e-05	0.000442	CcSEcCtD
Sunitinib—Diarrhoea—Azathioprine—systemic scleroderma	5.81e-05	0.000438	CcSEcCtD
Sunitinib—Haemoglobin—Prednisone—systemic scleroderma	5.79e-05	0.000436	CcSEcCtD
Sunitinib—Nausea—Captopril—systemic scleroderma	5.78e-05	0.000436	CcSEcCtD
Sunitinib—Abdominal discomfort—Methotrexate—systemic scleroderma	5.76e-05	0.000435	CcSEcCtD
Sunitinib—Haemorrhage—Prednisone—systemic scleroderma	5.76e-05	0.000434	CcSEcCtD
Sunitinib—Anorexia—Mycophenolate mofetil—systemic scleroderma	5.75e-05	0.000434	CcSEcCtD
Sunitinib—Asthenia—Leflunomide—systemic scleroderma	5.75e-05	0.000434	CcSEcCtD
Sunitinib—Pancytopenia—Methotrexate—systemic scleroderma	5.71e-05	0.000431	CcSEcCtD
Sunitinib—Pruritus—Leflunomide—systemic scleroderma	5.67e-05	0.000428	CcSEcCtD
Sunitinib—Connective tissue disorder—Prednisone—systemic scleroderma	5.66e-05	0.000427	CcSEcCtD
Sunitinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	5.63e-05	0.000425	CcSEcCtD
Sunitinib—Neutropenia—Methotrexate—systemic scleroderma	5.62e-05	0.000424	CcSEcCtD
Sunitinib—Dizziness—Azathioprine—systemic scleroderma	5.61e-05	0.000423	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	5.59e-05	0.000421	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	5.5e-05	0.000415	CcSEcCtD
Sunitinib—Asthenia—Mycophenolic acid—systemic scleroderma	5.49e-05	0.000414	CcSEcCtD
Sunitinib—Diarrhoea—Leflunomide—systemic scleroderma	5.48e-05	0.000414	CcSEcCtD
Sunitinib—Insomnia—Mycophenolate mofetil—systemic scleroderma	5.46e-05	0.000412	CcSEcCtD
Sunitinib—Abdominal pain—Lisinopril—systemic scleroderma	5.45e-05	0.000411	CcSEcCtD
Sunitinib—Body temperature increased—Lisinopril—systemic scleroderma	5.45e-05	0.000411	CcSEcCtD
Sunitinib—ABCG2—lung—systemic scleroderma	5.43e-05	0.000549	CbGeAlD
Sunitinib—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	5.42e-05	0.000409	CcSEcCtD
Sunitinib—Pruritus—Mycophenolic acid—systemic scleroderma	5.41e-05	0.000408	CcSEcCtD
Sunitinib—Vomiting—Azathioprine—systemic scleroderma	5.4e-05	0.000407	CcSEcCtD
Sunitinib—Pneumonia—Methotrexate—systemic scleroderma	5.39e-05	0.000407	CcSEcCtD
Sunitinib—Eye disorder—Prednisone—systemic scleroderma	5.38e-05	0.000406	CcSEcCtD
Sunitinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	5.38e-05	0.000406	CcSEcCtD
Sunitinib—Infestation NOS—Methotrexate—systemic scleroderma	5.36e-05	0.000404	CcSEcCtD
Sunitinib—Infestation—Methotrexate—systemic scleroderma	5.36e-05	0.000404	CcSEcCtD
Sunitinib—Rash—Azathioprine—systemic scleroderma	5.35e-05	0.000404	CcSEcCtD
Sunitinib—Dermatitis—Azathioprine—systemic scleroderma	5.35e-05	0.000403	CcSEcCtD
Sunitinib—Depression—Methotrexate—systemic scleroderma	5.35e-05	0.000403	CcSEcCtD
Sunitinib—Flushing—Prednisone—systemic scleroderma	5.34e-05	0.000403	CcSEcCtD
Sunitinib—Headache—Azathioprine—systemic scleroderma	5.32e-05	0.000401	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	5.31e-05	0.000401	CcSEcCtD
Sunitinib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	5.31e-05	0.000401	CcSEcCtD
Sunitinib—Dizziness—Leflunomide—systemic scleroderma	5.3e-05	0.0004	CcSEcCtD
Sunitinib—Renal failure—Methotrexate—systemic scleroderma	5.27e-05	0.000397	CcSEcCtD
Sunitinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	5.25e-05	0.000396	CcSEcCtD
Sunitinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	5.23e-05	0.000395	CcSEcCtD
Sunitinib—Stomatitis—Methotrexate—systemic scleroderma	5.23e-05	0.000394	CcSEcCtD
Sunitinib—Angiopathy—Prednisone—systemic scleroderma	5.22e-05	0.000394	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	5.21e-05	0.000393	CcSEcCtD
Sunitinib—Immune system disorder—Prednisone—systemic scleroderma	5.2e-05	0.000392	CcSEcCtD
Sunitinib—Pain—Mycophenolate mofetil—systemic scleroderma	5.16e-05	0.000389	CcSEcCtD
Sunitinib—Constipation—Mycophenolate mofetil—systemic scleroderma	5.16e-05	0.000389	CcSEcCtD
Sunitinib—Arrhythmia—Prednisone—systemic scleroderma	5.14e-05	0.000388	CcSEcCtD
Sunitinib—CSNK1E—Dexamethasone—Prednisone—systemic scleroderma	5.12e-05	0.0201	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Prednisone—systemic scleroderma	5.12e-05	0.0201	CbGdCrCtD
Sunitinib—Vomiting—Leflunomide—systemic scleroderma	5.1e-05	0.000384	CcSEcCtD
Sunitinib—Alopecia—Prednisone—systemic scleroderma	5.09e-05	0.000384	CcSEcCtD
Sunitinib—Hypersensitivity—Lisinopril—systemic scleroderma	5.07e-05	0.000383	CcSEcCtD
Sunitinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	5.07e-05	0.000382	CcSEcCtD
Sunitinib—Dizziness—Mycophenolic acid—systemic scleroderma	5.06e-05	0.000381	CcSEcCtD
Sunitinib—Epistaxis—Methotrexate—systemic scleroderma	5.06e-05	0.000381	CcSEcCtD
Sunitinib—Rash—Leflunomide—systemic scleroderma	5.05e-05	0.000381	CcSEcCtD
Sunitinib—Dermatitis—Leflunomide—systemic scleroderma	5.05e-05	0.000381	CcSEcCtD
Sunitinib—Mental disorder—Prednisone—systemic scleroderma	5.04e-05	0.00038	CcSEcCtD
Sunitinib—Nausea—Azathioprine—systemic scleroderma	5.04e-05	0.00038	CcSEcCtD
Sunitinib—CYP3A5—lung—systemic scleroderma	5.04e-05	0.00051	CbGeAlD
Sunitinib—Headache—Leflunomide—systemic scleroderma	5.02e-05	0.000379	CcSEcCtD
Sunitinib—Malnutrition—Prednisone—systemic scleroderma	5.01e-05	0.000378	CcSEcCtD
Sunitinib—Erythema—Prednisone—systemic scleroderma	5.01e-05	0.000378	CcSEcCtD
Sunitinib—Asthenia—Lisinopril—systemic scleroderma	4.94e-05	0.000373	CcSEcCtD
Sunitinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	4.93e-05	0.000372	CcSEcCtD
Sunitinib—Pruritus—Lisinopril—systemic scleroderma	4.87e-05	0.000368	CcSEcCtD
Sunitinib—Vomiting—Mycophenolic acid—systemic scleroderma	4.86e-05	0.000367	CcSEcCtD
Sunitinib—Haemoglobin—Methotrexate—systemic scleroderma	4.84e-05	0.000365	CcSEcCtD
Sunitinib—Rash—Mycophenolic acid—systemic scleroderma	4.82e-05	0.000364	CcSEcCtD
Sunitinib—Dermatitis—Mycophenolic acid—systemic scleroderma	4.82e-05	0.000363	CcSEcCtD
Sunitinib—Haemorrhage—Methotrexate—systemic scleroderma	4.81e-05	0.000363	CcSEcCtD
Sunitinib—Hepatitis—Methotrexate—systemic scleroderma	4.81e-05	0.000363	CcSEcCtD
Sunitinib—Headache—Mycophenolic acid—systemic scleroderma	4.79e-05	0.000361	CcSEcCtD
Sunitinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	4.77e-05	0.00036	CcSEcCtD
Sunitinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	4.77e-05	0.00036	CcSEcCtD
Sunitinib—Nausea—Leflunomide—systemic scleroderma	4.76e-05	0.000359	CcSEcCtD
Sunitinib—Urinary tract disorder—Methotrexate—systemic scleroderma	4.75e-05	0.000358	CcSEcCtD
Sunitinib—Urethral disorder—Methotrexate—systemic scleroderma	4.72e-05	0.000356	CcSEcCtD
Sunitinib—Diarrhoea—Lisinopril—systemic scleroderma	4.71e-05	0.000355	CcSEcCtD
Sunitinib—Anaemia—Prednisone—systemic scleroderma	4.63e-05	0.000349	CcSEcCtD
Sunitinib—Angioedema—Prednisone—systemic scleroderma	4.58e-05	0.000345	CcSEcCtD
Sunitinib—Dizziness—Lisinopril—systemic scleroderma	4.55e-05	0.000344	CcSEcCtD
Sunitinib—Erythema multiforme—Methotrexate—systemic scleroderma	4.55e-05	0.000343	CcSEcCtD
Sunitinib—Nausea—Mycophenolic acid—systemic scleroderma	4.54e-05	0.000343	CcSEcCtD
Sunitinib—CYP3A4—digestive system—systemic scleroderma	4.53e-05	0.000458	CbGeAlD
Sunitinib—Eye disorder—Methotrexate—systemic scleroderma	4.5e-05	0.000339	CcSEcCtD
Sunitinib—Cardiac disorder—Methotrexate—systemic scleroderma	4.47e-05	0.000337	CcSEcCtD
Sunitinib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	4.45e-05	0.000335	CcSEcCtD
Sunitinib—Vomiting—Lisinopril—systemic scleroderma	4.38e-05	0.00033	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—systemic scleroderma	4.37e-05	0.000329	CcSEcCtD
Sunitinib—Immune system disorder—Methotrexate—systemic scleroderma	4.35e-05	0.000328	CcSEcCtD
Sunitinib—Rash—Lisinopril—systemic scleroderma	4.34e-05	0.000328	CcSEcCtD
Sunitinib—Convulsion—Prednisone—systemic scleroderma	4.34e-05	0.000328	CcSEcCtD
Sunitinib—Dermatitis—Lisinopril—systemic scleroderma	4.34e-05	0.000327	CcSEcCtD
Sunitinib—Mediastinal disorder—Methotrexate—systemic scleroderma	4.34e-05	0.000327	CcSEcCtD
Sunitinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	4.33e-05	0.000327	CcSEcCtD
Sunitinib—Hypertension—Prednisone—systemic scleroderma	4.33e-05	0.000326	CcSEcCtD
Sunitinib—Chills—Methotrexate—systemic scleroderma	4.32e-05	0.000326	CcSEcCtD
Sunitinib—Headache—Lisinopril—systemic scleroderma	4.32e-05	0.000325	CcSEcCtD
Sunitinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	4.27e-05	0.000322	CcSEcCtD
Sunitinib—Arthralgia—Prednisone—systemic scleroderma	4.27e-05	0.000322	CcSEcCtD
Sunitinib—Myalgia—Prednisone—systemic scleroderma	4.27e-05	0.000322	CcSEcCtD
Sunitinib—Alopecia—Methotrexate—systemic scleroderma	4.25e-05	0.000321	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	4.24e-05	0.00032	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—systemic scleroderma	4.22e-05	0.000318	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—systemic scleroderma	4.19e-05	0.000316	CcSEcCtD
Sunitinib—Erythema—Methotrexate—systemic scleroderma	4.19e-05	0.000316	CcSEcCtD
Sunitinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	4.13e-05	0.000311	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—systemic scleroderma	4.1e-05	0.000309	CcSEcCtD
Sunitinib—CHEK2—Danazol—Prednisone—systemic scleroderma	4.1e-05	0.0161	CbGdCrCtD
Sunitinib—Nausea—Lisinopril—systemic scleroderma	4.09e-05	0.000309	CcSEcCtD
Sunitinib—Oedema—Prednisone—systemic scleroderma	4.09e-05	0.000309	CcSEcCtD
Sunitinib—Infection—Prednisone—systemic scleroderma	4.06e-05	0.000307	CcSEcCtD
Sunitinib—Back pain—Methotrexate—systemic scleroderma	4.05e-05	0.000306	CcSEcCtD
Sunitinib—Shock—Prednisone—systemic scleroderma	4.02e-05	0.000304	CcSEcCtD
Sunitinib—Nervous system disorder—Prednisone—systemic scleroderma	4.01e-05	0.000303	CcSEcCtD
Sunitinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.99e-05	0.000301	CcSEcCtD
Sunitinib—Skin disorder—Prednisone—systemic scleroderma	3.97e-05	0.0003	CcSEcCtD
Sunitinib—Anorexia—Prednisone—systemic scleroderma	3.9e-05	0.000294	CcSEcCtD
Sunitinib—Anaemia—Methotrexate—systemic scleroderma	3.87e-05	0.000292	CcSEcCtD
Sunitinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.84e-05	0.000289	CcSEcCtD
Sunitinib—Rash—Mycophenolate mofetil—systemic scleroderma	3.81e-05	0.000287	CcSEcCtD
Sunitinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.8e-05	0.000287	CcSEcCtD
Sunitinib—Headache—Mycophenolate mofetil—systemic scleroderma	3.78e-05	0.000285	CcSEcCtD
Sunitinib—Leukopenia—Methotrexate—systemic scleroderma	3.75e-05	0.000283	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	3.73e-05	0.000281	CcSEcCtD
Sunitinib—Insomnia—Prednisone—systemic scleroderma	3.7e-05	0.000279	CcSEcCtD
Sunitinib—Paraesthesia—Prednisone—systemic scleroderma	3.67e-05	0.000277	CcSEcCtD
Sunitinib—Cough—Methotrexate—systemic scleroderma	3.66e-05	0.000276	CcSEcCtD
Sunitinib—Convulsion—Methotrexate—systemic scleroderma	3.63e-05	0.000274	CcSEcCtD
Sunitinib—Dyspepsia—Prednisone—systemic scleroderma	3.6e-05	0.000272	CcSEcCtD
Sunitinib—Nausea—Mycophenolate mofetil—systemic scleroderma	3.58e-05	0.00027	CcSEcCtD
Sunitinib—Chest pain—Methotrexate—systemic scleroderma	3.57e-05	0.000269	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—systemic scleroderma	3.57e-05	0.000269	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—systemic scleroderma	3.57e-05	0.000269	CcSEcCtD
Sunitinib—Decreased appetite—Prednisone—systemic scleroderma	3.56e-05	0.000268	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	3.54e-05	0.000267	CcSEcCtD
Sunitinib—Fatigue—Prednisone—systemic scleroderma	3.53e-05	0.000266	CcSEcCtD
Sunitinib—Constipation—Prednisone—systemic scleroderma	3.5e-05	0.000264	CcSEcCtD
Sunitinib—Infection—Methotrexate—systemic scleroderma	3.4e-05	0.000256	CcSEcCtD
Sunitinib—Nervous system disorder—Methotrexate—systemic scleroderma	3.35e-05	0.000253	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—systemic scleroderma	3.35e-05	0.000252	CcSEcCtD
Sunitinib—Gastrointestinal pain—Prednisone—systemic scleroderma	3.35e-05	0.000252	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—systemic scleroderma	3.32e-05	0.00025	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—systemic scleroderma	3.26e-05	0.000246	CcSEcCtD
Sunitinib—Abdominal pain—Prednisone—systemic scleroderma	3.23e-05	0.000244	CcSEcCtD
Sunitinib—Body temperature increased—Prednisone—systemic scleroderma	3.23e-05	0.000244	CcSEcCtD
Sunitinib—ABCB1—digestive system—systemic scleroderma	3.21e-05	0.000324	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3.11e-05	0.000235	CcSEcCtD
Sunitinib—Insomnia—Methotrexate—systemic scleroderma	3.09e-05	0.000233	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—systemic scleroderma	3.07e-05	0.000232	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—systemic scleroderma	3.05e-05	0.00023	CcSEcCtD
Sunitinib—Hypersensitivity—Prednisone—systemic scleroderma	3.01e-05	0.000227	CcSEcCtD
Sunitinib—Dyspepsia—Methotrexate—systemic scleroderma	3.01e-05	0.000227	CcSEcCtD
Sunitinib—Decreased appetite—Methotrexate—systemic scleroderma	2.97e-05	0.000224	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.95e-05	0.000223	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—systemic scleroderma	2.95e-05	0.000222	CcSEcCtD
Sunitinib—Asthenia—Prednisone—systemic scleroderma	2.94e-05	0.000221	CcSEcCtD
Sunitinib—Pain—Methotrexate—systemic scleroderma	2.92e-05	0.000221	CcSEcCtD
Sunitinib—Pruritus—Prednisone—systemic scleroderma	2.89e-05	0.000218	CcSEcCtD
Sunitinib—Diarrhoea—Prednisone—systemic scleroderma	2.8e-05	0.000211	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.8e-05	0.000211	CcSEcCtD
Sunitinib—Dizziness—Prednisone—systemic scleroderma	2.71e-05	0.000204	CcSEcCtD
Sunitinib—Body temperature increased—Methotrexate—systemic scleroderma	2.7e-05	0.000204	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—systemic scleroderma	2.7e-05	0.000204	CcSEcCtD
Sunitinib—ABCB1—lung—systemic scleroderma	2.68e-05	0.000271	CbGeAlD
Sunitinib—Vomiting—Prednisone—systemic scleroderma	2.6e-05	0.000196	CcSEcCtD
Sunitinib—Rash—Prednisone—systemic scleroderma	2.58e-05	0.000195	CcSEcCtD
Sunitinib—Dermatitis—Prednisone—systemic scleroderma	2.58e-05	0.000194	CcSEcCtD
Sunitinib—Headache—Prednisone—systemic scleroderma	2.56e-05	0.000193	CcSEcCtD
Sunitinib—Hypersensitivity—Methotrexate—systemic scleroderma	2.52e-05	0.00019	CcSEcCtD
Sunitinib—Asthenia—Methotrexate—systemic scleroderma	2.45e-05	0.000185	CcSEcCtD
Sunitinib—Nausea—Prednisone—systemic scleroderma	2.43e-05	0.000183	CcSEcCtD
Sunitinib—Pruritus—Methotrexate—systemic scleroderma	2.42e-05	0.000182	CcSEcCtD
Sunitinib—Diarrhoea—Methotrexate—systemic scleroderma	2.34e-05	0.000176	CcSEcCtD
Sunitinib—Dizziness—Methotrexate—systemic scleroderma	2.26e-05	0.000171	CcSEcCtD
Sunitinib—Vomiting—Methotrexate—systemic scleroderma	2.17e-05	0.000164	CcSEcCtD
Sunitinib—Rash—Methotrexate—systemic scleroderma	2.16e-05	0.000163	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—systemic scleroderma	2.15e-05	0.000162	CcSEcCtD
Sunitinib—Headache—Methotrexate—systemic scleroderma	2.14e-05	0.000162	CcSEcCtD
Sunitinib—Nausea—Methotrexate—systemic scleroderma	2.03e-05	0.000153	CcSEcCtD
Sunitinib—MAP2K2—Signaling by GPCR—EDN1—systemic scleroderma	5.21e-06	4.21e-05	CbGpPWpGaD
Sunitinib—FYN—Hemostasis—NOS3—systemic scleroderma	5.21e-06	4.2e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CSK—systemic scleroderma	5.17e-06	4.17e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—HSPG2—systemic scleroderma	5.16e-06	4.17e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—IL1A—systemic scleroderma	5.14e-06	4.15e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CSK—systemic scleroderma	5.14e-06	4.15e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Disease—NOS3—systemic scleroderma	5.13e-06	4.14e-05	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—EDN1—systemic scleroderma	5.13e-06	4.14e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—IL1A—systemic scleroderma	5.13e-06	4.14e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—HSPG2—systemic scleroderma	5.11e-06	4.13e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—CD40LG—systemic scleroderma	5.11e-06	4.13e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—CD40LG—systemic scleroderma	5.1e-06	4.12e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HSPG2—systemic scleroderma	5.09e-06	4.11e-05	CbGpPWpGaD
Sunitinib—TBK1—Immune System—IL1B—systemic scleroderma	5.07e-06	4.09e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—EDN1—systemic scleroderma	5.02e-06	4.06e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—CCL2—systemic scleroderma	4.99e-06	4.03e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—NOS3—systemic scleroderma	4.99e-06	4.03e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HLA-DQB1—systemic scleroderma	4.98e-06	4.02e-05	CbGpPWpGaD
Sunitinib—CAMK2G—Immune System—IL1B—systemic scleroderma	4.98e-06	4.02e-05	CbGpPWpGaD
Sunitinib—JAK2—Hemostasis—NOS3—systemic scleroderma	4.95e-06	3.99e-05	CbGpPWpGaD
Sunitinib—FGFR1—Developmental Biology—MMP9—systemic scleroderma	4.92e-06	3.97e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CSK—systemic scleroderma	4.91e-06	3.96e-05	CbGpPWpGaD
Sunitinib—STK11—Signaling Pathways—MMP9—systemic scleroderma	4.89e-06	3.95e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—EDN1—systemic scleroderma	4.88e-06	3.94e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HLA-DQB1—systemic scleroderma	4.86e-06	3.93e-05	CbGpPWpGaD
Sunitinib—MAP3K3—Immune System—IL1B—systemic scleroderma	4.86e-06	3.93e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—EDN1—systemic scleroderma	4.84e-06	3.91e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—EDN1—systemic scleroderma	4.81e-06	3.88e-05	CbGpPWpGaD
Sunitinib—YES1—Developmental Biology—TGFB1—systemic scleroderma	4.78e-06	3.86e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL1A—systemic scleroderma	4.73e-06	3.82e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—NOS3—systemic scleroderma	4.72e-06	3.81e-05	CbGpPWpGaD
Sunitinib—INSR—Signaling Pathways—MMP9—systemic scleroderma	4.71e-06	3.8e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—CD40LG—systemic scleroderma	4.71e-06	3.8e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—CCL2—systemic scleroderma	4.71e-06	3.8e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—HLA-DQB1—systemic scleroderma	4.69e-06	3.79e-05	CbGpPWpGaD
Sunitinib—YES1—Hemostasis—TGFB1—systemic scleroderma	4.69e-06	3.79e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—CCL2—systemic scleroderma	4.67e-06	3.77e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—NOS3—systemic scleroderma	4.67e-06	3.77e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HLA-DQB1—systemic scleroderma	4.66e-06	3.77e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—EDN1—systemic scleroderma	4.66e-06	3.76e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—EDN1—systemic scleroderma	4.66e-06	3.76e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—EDN1—systemic scleroderma	4.66e-06	3.76e-05	CbGpPWpGaD
Sunitinib—CSNK1G2—Signaling Pathways—TGFB1—systemic scleroderma	4.65e-06	3.75e-05	CbGpPWpGaD
Sunitinib—GRK1—Signaling Pathways—TGFB1—systemic scleroderma	4.65e-06	3.75e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL1A—systemic scleroderma	4.62e-06	3.73e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—CD40LG—systemic scleroderma	4.59e-06	3.71e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—EDN1—systemic scleroderma	4.54e-06	3.67e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Developmental Biology—MMP9—systemic scleroderma	4.53e-06	3.65e-05	CbGpPWpGaD
Sunitinib—IRAK4—Immune System—IL1B—systemic scleroderma	4.52e-06	3.65e-05	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—MMP9—systemic scleroderma	4.47e-06	3.61e-05	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—MMP9—systemic scleroderma	4.47e-06	3.61e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HLA-DQB1—systemic scleroderma	4.46e-06	3.6e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL1A—systemic scleroderma	4.45e-06	3.6e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—NOS3—systemic scleroderma	4.45e-06	3.59e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL1A—systemic scleroderma	4.43e-06	3.58e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—CD40LG—systemic scleroderma	4.43e-06	3.57e-05	CbGpPWpGaD
Sunitinib—AXL—Signaling Pathways—TGFB1—systemic scleroderma	4.41e-06	3.56e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—CD40LG—systemic scleroderma	4.4e-06	3.56e-05	CbGpPWpGaD
Sunitinib—TYK2—Developmental Biology—TGFB1—systemic scleroderma	4.4e-06	3.55e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Immune System—IL1B—systemic scleroderma	4.4e-06	3.55e-05	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—MMP9—systemic scleroderma	4.34e-06	3.5e-05	CbGpPWpGaD
Sunitinib—FYN—Developmental Biology—MMP9—systemic scleroderma	4.26e-06	3.44e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Developmental Biology—MMP9—systemic scleroderma	4.23e-06	3.42e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL1A—systemic scleroderma	4.23e-06	3.42e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—CD40LG—systemic scleroderma	4.21e-06	3.4e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—CCL2—systemic scleroderma	4.2e-06	3.39e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Disease—TGFB1—systemic scleroderma	4.2e-06	3.39e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—NOS3—systemic scleroderma	4.19e-06	3.39e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—NOS3—systemic scleroderma	4.16e-06	3.36e-05	CbGpPWpGaD
Sunitinib—FGFR1—Developmental Biology—TGFB1—systemic scleroderma	4.05e-06	3.27e-05	CbGpPWpGaD
Sunitinib—JAK2—Developmental Biology—MMP9—systemic scleroderma	4.05e-06	3.27e-05	CbGpPWpGaD
Sunitinib—STK11—Signaling Pathways—TGFB1—systemic scleroderma	4.03e-06	3.26e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—CCL2—systemic scleroderma	4.03e-06	3.26e-05	CbGpPWpGaD
Sunitinib—PTK2B—Immune System—IL1B—systemic scleroderma	4.03e-06	3.25e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—MMP9—systemic scleroderma	4e-06	3.23e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—EDN1—systemic scleroderma	3.95e-06	3.19e-05	CbGpPWpGaD
Sunitinib—BLK—Immune System—IL1B—systemic scleroderma	3.93e-06	3.17e-05	CbGpPWpGaD
Sunitinib—FGR—Immune System—IL1B—systemic scleroderma	3.92e-06	3.16e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—CTGF—systemic scleroderma	3.91e-06	3.16e-05	CbGpPWpGaD
Sunitinib—INSR—Signaling Pathways—TGFB1—systemic scleroderma	3.88e-06	3.13e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—CTGF—systemic scleroderma	3.88e-06	3.13e-05	CbGpPWpGaD
Sunitinib—ABCC4—Hemostasis—TGFB1—systemic scleroderma	3.79e-06	3.06e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—MMP9—systemic scleroderma	3.78e-06	3.06e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—CCL2—systemic scleroderma	3.78e-06	3.05e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—CCL2—systemic scleroderma	3.75e-06	3.03e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—MMP9—systemic scleroderma	3.75e-06	3.02e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EDN1—systemic scleroderma	3.74e-06	3.02e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Developmental Biology—TGFB1—systemic scleroderma	3.73e-06	3.01e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—HSPG2—systemic scleroderma	3.7e-06	2.98e-05	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—TGFB1—systemic scleroderma	3.69e-06	2.98e-05	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—TGFB1—systemic scleroderma	3.69e-06	2.98e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EDN1—systemic scleroderma	3.63e-06	2.93e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—NOS3—systemic scleroderma	3.59e-06	2.9e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EDN1—systemic scleroderma	3.59e-06	2.9e-05	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—TGFB1—systemic scleroderma	3.58e-06	2.89e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—MMP9—systemic scleroderma	3.57e-06	2.88e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—CCL2—systemic scleroderma	3.56e-06	2.88e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EDN1—systemic scleroderma	3.52e-06	2.84e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EDN1—systemic scleroderma	3.52e-06	2.84e-05	CbGpPWpGaD
Sunitinib—FYN—Developmental Biology—TGFB1—systemic scleroderma	3.51e-06	2.83e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Developmental Biology—TGFB1—systemic scleroderma	3.49e-06	2.82e-05	CbGpPWpGaD
Sunitinib—FYN—Hemostasis—TGFB1—systemic scleroderma	3.44e-06	2.78e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—CCL2—systemic scleroderma	3.43e-06	2.77e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Disease—TGFB1—systemic scleroderma	3.39e-06	2.74e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—NOS3—systemic scleroderma	3.37e-06	2.72e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—MMP9—systemic scleroderma	3.36e-06	2.72e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EDN1—systemic scleroderma	3.34e-06	2.7e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—NOS3—systemic scleroderma	3.34e-06	2.7e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—MMP9—systemic scleroderma	3.34e-06	2.7e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EDN1—systemic scleroderma	3.34e-06	2.69e-05	CbGpPWpGaD
Sunitinib—JAK2—Developmental Biology—TGFB1—systemic scleroderma	3.34e-06	2.69e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—CCL2—systemic scleroderma	3.33e-06	2.69e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—CCL2—systemic scleroderma	3.31e-06	2.67e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—TGFB1—systemic scleroderma	3.3e-06	2.66e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—CCL2—systemic scleroderma	3.29e-06	2.65e-05	CbGpPWpGaD
Sunitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.27e-06	2.64e-05	CbGpPWpGaD
Sunitinib—JAK2—Hemostasis—TGFB1—systemic scleroderma	3.27e-06	2.64e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—CCL2—systemic scleroderma	3.19e-06	2.57e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—CCL2—systemic scleroderma	3.19e-06	2.57e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—CCL2—systemic scleroderma	3.19e-06	2.57e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—IL1B—systemic scleroderma	3.16e-06	2.55e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—NOS3—systemic scleroderma	3.16e-06	2.55e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—NOS3—systemic scleroderma	3.12e-06	2.52e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—TGFB1—systemic scleroderma	3.12e-06	2.52e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—CCL2—systemic scleroderma	3.11e-06	2.51e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—TGFB1—systemic scleroderma	3.09e-06	2.49e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EDN1—systemic scleroderma	3.08e-06	2.49e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—NOS3—systemic scleroderma	3.07e-06	2.47e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—NOS3—systemic scleroderma	3.06e-06	2.47e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EDN1—systemic scleroderma	3e-06	2.43e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—IL1B—systemic scleroderma	3e-06	2.42e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—NOS3—systemic scleroderma	2.95e-06	2.38e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—TGFB1—systemic scleroderma	2.94e-06	2.37e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—NOS3—systemic scleroderma	2.93e-06	2.37e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—IL1B—systemic scleroderma	2.91e-06	2.35e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—NOS3—systemic scleroderma	2.91e-06	2.35e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—NOS3—systemic scleroderma	2.9e-06	2.34e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EDN1—systemic scleroderma	2.9e-06	2.34e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—MMP9—systemic scleroderma	2.88e-06	2.33e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EDN1—systemic scleroderma	2.88e-06	2.33e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—IL1B—systemic scleroderma	2.88e-06	2.32e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—NOS3—systemic scleroderma	2.84e-06	2.29e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—NOS3—systemic scleroderma	2.84e-06	2.29e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—IL1B—systemic scleroderma	2.83e-06	2.28e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—IL1B—systemic scleroderma	2.83e-06	2.28e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—CTGF—systemic scleroderma	2.8e-06	2.26e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	2.79e-06	2.25e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—TGFB1—systemic scleroderma	2.77e-06	2.24e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—NOS3—systemic scleroderma	2.77e-06	2.24e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EDN1—systemic scleroderma	2.75e-06	2.22e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—TGFB1—systemic scleroderma	2.75e-06	2.22e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—MMP9—systemic scleroderma	2.71e-06	2.18e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CCL2—systemic scleroderma	2.7e-06	2.18e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—IL1B—systemic scleroderma	2.68e-06	2.16e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—MMP9—systemic scleroderma	2.68e-06	2.16e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—NOS3—systemic scleroderma	2.68e-06	2.16e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—IL1B—systemic scleroderma	2.67e-06	2.16e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—NOS3—systemic scleroderma	2.61e-06	2.11e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CCL2—systemic scleroderma	2.56e-06	2.07e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—NOS3—systemic scleroderma	2.52e-06	2.03e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—NOS3—systemic scleroderma	2.51e-06	2.02e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CCL2—systemic scleroderma	2.48e-06	2e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL1B—systemic scleroderma	2.47e-06	1.99e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—MMP9—systemic scleroderma	2.46e-06	1.98e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CCL2—systemic scleroderma	2.45e-06	1.98e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL1B—systemic scleroderma	2.41e-06	1.95e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CCL2—systemic scleroderma	2.41e-06	1.94e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CCL2—systemic scleroderma	2.41e-06	1.94e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—NOS3—systemic scleroderma	2.4e-06	1.94e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—NOS3—systemic scleroderma	2.4e-06	1.93e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TGFB1—systemic scleroderma	2.38e-06	1.92e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MMP9—systemic scleroderma	2.37e-06	1.91e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MMP9—systemic scleroderma	2.35e-06	1.9e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL1B—systemic scleroderma	2.32e-06	1.88e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL1B—systemic scleroderma	2.31e-06	1.86e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CCL2—systemic scleroderma	2.29e-06	1.85e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—NOS3—systemic scleroderma	2.28e-06	1.84e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CCL2—systemic scleroderma	2.28e-06	1.84e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MMP9—systemic scleroderma	2.28e-06	1.84e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MMP9—systemic scleroderma	2.28e-06	1.84e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TGFB1—systemic scleroderma	2.23e-06	1.8e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MMP9—systemic scleroderma	2.22e-06	1.79e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—NOS3—systemic scleroderma	2.21e-06	1.79e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TGFB1—systemic scleroderma	2.21e-06	1.78e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL1B—systemic scleroderma	2.21e-06	1.78e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—NOS3—systemic scleroderma	2.19e-06	1.76e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NOS3—systemic scleroderma	2.15e-06	1.73e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NOS3—systemic scleroderma	2.15e-06	1.73e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CTGF—systemic scleroderma	2.11e-06	1.71e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCL2—systemic scleroderma	2.1e-06	1.7e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—TGFB1—systemic scleroderma	2.09e-06	1.69e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—TGFB1—systemic scleroderma	2.06e-06	1.67e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCL2—systemic scleroderma	2.05e-06	1.66e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NOS3—systemic scleroderma	2.04e-06	1.64e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NOS3—systemic scleroderma	2.03e-06	1.64e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—TGFB1—systemic scleroderma	2.03e-06	1.64e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TGFB1—systemic scleroderma	2.02e-06	1.63e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCL2—systemic scleroderma	1.98e-06	1.6e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCL2—systemic scleroderma	1.97e-06	1.59e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TGFB1—systemic scleroderma	1.95e-06	1.57e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TGFB1—systemic scleroderma	1.94e-06	1.56e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MMP9—systemic scleroderma	1.93e-06	1.56e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—TGFB1—systemic scleroderma	1.92e-06	1.55e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—TGFB1—systemic scleroderma	1.92e-06	1.55e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCL2—systemic scleroderma	1.88e-06	1.52e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TGFB1—systemic scleroderma	1.88e-06	1.52e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TGFB1—systemic scleroderma	1.88e-06	1.52e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NOS3—systemic scleroderma	1.88e-06	1.51e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NOS3—systemic scleroderma	1.83e-06	1.48e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TGFB1—systemic scleroderma	1.83e-06	1.48e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MMP9—systemic scleroderma	1.83e-06	1.48e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MMP9—systemic scleroderma	1.78e-06	1.43e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—TGFB1—systemic scleroderma	1.77e-06	1.43e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NOS3—systemic scleroderma	1.76e-06	1.42e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NOS3—systemic scleroderma	1.76e-06	1.42e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MMP9—systemic scleroderma	1.75e-06	1.42e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—TGFB1—systemic scleroderma	1.73e-06	1.4e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MMP9—systemic scleroderma	1.72e-06	1.39e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MMP9—systemic scleroderma	1.72e-06	1.39e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.72e-06	1.39e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—NOS3—systemic scleroderma	1.7e-06	1.37e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—NOS3—systemic scleroderma	1.69e-06	1.36e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NOS3—systemic scleroderma	1.68e-06	1.35e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—TGFB1—systemic scleroderma	1.67e-06	1.35e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—TGFB1—systemic scleroderma	1.66e-06	1.34e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MMP9—systemic scleroderma	1.63e-06	1.32e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MMP9—systemic scleroderma	1.63e-06	1.32e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TGFB1—systemic scleroderma	1.59e-06	1.28e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—TGFB1—systemic scleroderma	1.58e-06	1.28e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TGFB1—systemic scleroderma	1.51e-06	1.22e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MMP9—systemic scleroderma	1.51e-06	1.22e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MMP9—systemic scleroderma	1.47e-06	1.19e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TGFB1—systemic scleroderma	1.46e-06	1.18e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TGFB1—systemic scleroderma	1.45e-06	1.17e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TGFB1—systemic scleroderma	1.42e-06	1.15e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TGFB1—systemic scleroderma	1.42e-06	1.15e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—systemic scleroderma	1.42e-06	1.14e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—systemic scleroderma	1.41e-06	1.14e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TGFB1—systemic scleroderma	1.35e-06	1.09e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—systemic scleroderma	1.35e-06	1.09e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TGFB1—systemic scleroderma	1.34e-06	1.08e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.3e-06	1.05e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TGFB1—systemic scleroderma	1.24e-06	1e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—NOS3—systemic scleroderma	1.22e-06	9.85e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TGFB1—systemic scleroderma	1.21e-06	9.77e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TGFB1—systemic scleroderma	1.17e-06	9.42e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TGFB1—systemic scleroderma	1.16e-06	9.37e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFB1—systemic scleroderma	1.11e-06	8.95e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—NOS3—systemic scleroderma	9.2e-07	7.43e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	5.67e-07	4.58e-06	CbGpPWpGaD
